The presence of androgen receptor variant 7 (AR-V7) variants becomes a significant hallmark of castration-resistant prostate cancer (CRPC) relapsed from hormonal therapy and is associated with poor survival of CRPC patients because of lacking a ligand-binding domain. Currently, it still lacks an effective agent to target AR-V7 or AR-Vs in general. Here, we showed that a novel class of agents (thailanstatins, TSTs and spliceostatin A analogs) can significantly suppress the expression of AR-V7 mRNA and protein but in a less extent on the full-length AR expression. Mechanistically, TST-D is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3 0 splice site. In vivo, TST-D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis. The machinery associated with AR gene splicing in CRPC is a potential target for drugs. Based on their potency in the suppression of AR-V7 responsible for the growth/survival of CRPC, TSTs representing a new class of anti-AR-V agents warrant further development into clinical application.
The presence of androgen receptor variant 7 (AR-V7) variants becomes a significant hallmark of castration-resistant prostate cancer (CRPC) relapsed from hormonal therapy and is associated with poor survival of CRPC patients because of lacking a ligand-binding domain. Currently, it still lacks an effective agent to target AR-V7 or AR-Vs in general. Here, we showed that a novel class of agents (thailanstatins, TSTs and spliceostatin A analogs) can significantly suppress the expression of AR-V7 mRNA and protein but in a less extent on the full-length AR expression. Mechanistically, TST-D is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3 0 splice site. In vivo, TST-D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis. The machinery associated with AR gene splicing in CRPC is a potential target for drugs. Based on their potency in the suppression of AR-V7 responsible for the growth/survival of CRPC, TSTs representing a new class of anti-AR-V agents warrant further development into clinical application.
Prostate cancer (PCa) has been the second common cause of cancer deaths in men only behind lung cancer in the past two decades. 1 Androgen receptor (AR) plays a central role in PCa development 2 ; even in castration-resistant PCa (CRPC) cells, AR or AR-mediated signaling pathways remain active. 3 Multiple mechanisms lead to hyperactive AR signaling, including AR mutation or amplification, altered expression of AR co-activators and co-repressors, AR activation through crosstalk with other signaling pathways or presence of AR splice variants (AR-Vs [4] [5] [6] [7] [8] . Therefore, there remains a critical and unmet need for novel therapeutic agents that can target AR signaling in CRPC. For patients with metastatic PCa, androgen deprivation therapy (ADT) is the standard treatment. The majority of advanced PCa patients respond to initial ADT temporarily, but they inevitably progress from an androgen-dependent stage to CRPC. 9 Currently, ADT is to either reduce androgen production by surgical or chemical castration or inhibit AR activity by blocking androgen binding to the C-terminal ligand-binding domain (LBD) of AR (i.e., antiandrogen), in which docking of AR antagonists into LBD results in the passive AR inhibition via competition with agonists. Although there are new available ADT agents such as cytochrome P450 17 (CYP17) inhibitor Abiraterone 10 and the androgen-receptor antagonist Enzalutamide (formerly known as MDV-3100), 11 ADT is not curative and only prolongs the relapse of CRPC. Surprisingly, recent studies have identified several constitutively active AR-Vs lacking the LBD. 12 In this case, even complete androgen ablation would have no effect on AR-V activity. In addition, AR-Vs also play a role in mechanism of resistance to chemotherapies such as Taxanes. 13 AR-Vs are refractory to traditional treatment, 11, 14 which highlights the need for a new class of AR-inhibitory agents for successful management of tumors expressing truncated ARs or AR-Vs. For example, the active AR inhibition may either prevent co-activator(s) binding or induce corepressor(s) recruitment to the N-terminal transactive domain, or suppress the expression of AR or AR-Vs. Currently, it is hypothesized that the formation of AR-Vs can occur through two different mechanisms: genomic rearrangement and alternative splicing. Genomic rearrangement of AR gene has been reported in PCa cell lines and clinical tissues, 15, 16 but it is still controversial because RNA-Seq studies did not detect it in the SU2C series. 17 Alternative splicing of AR precursor mRNA (pre-mRNA) is a common mechanism for generating a variety of AR-V proteins expressed in PCa cell lines and specimens. 18 It is known that >90% of human genes undergo programmed alternative splicing to generate protein variants far greater than 30,000 encoding genes. 19 While this process inherently provides for transcriptome diversity, aberrant alternative splicing has been implicated in numerous disease conditions such as cancer and neurodegeneration. 20, 21 In malignancies, alternative splicing of the pre-mRNAs of oncogenes is frequent mechanism used by the cell to generate protein variants that have oncogenic activity. 21 Thus, targeting aberrant pre-mRNA alternative splicing represents a new opportunity and strategy to eradicate recurrent CRPC expressing AR-Vs. In this study, we explored novel spliceosome inhibitors as potential therapeutic agents using CRPC model in vivo and identified their mechanism of action in vitro.
Material and Methods
Cell culture, antibodies and reagents PNT1A, LAPC-4, 22RV1, PZ-HPV7, RWPE-1 and HEK293 were purchased from American Type Culture Collection (ATCC, Manassas, VA) and were maintained in medium according to ATCC instruction. C4-2 was originally generated by our lab. Table S1 .
Preparation of thailanstatins from Burkholderia thailandensis
MSMB43. Thailanstatin A (TST-A; Supporting Information, Fig. S1 ) was purified to at least 95% homogeneity from the fermentation broth of Burkholderia thailandensis MSMB43 as previously described. 22 Thailanstatin D (TST-D), an analog of TST-A without a hydroxyl group on the heavily substituted tetrahydrofuran ring (Supporting Information, Fig. S1 ), was newly discovered and purified similarly as TST-A from the fermentation broth of an engineered bacterial strain. 23 Diaion HP-20 resin (Sigma-Aldrich, St. Louis, MO) was a key reagent used for the purification of TSTs. The final compound preparations were verified by mass spectrometry (MS) and by nuclear magnetic resonance (NMR) analysis.
Crystal violet assay for in vitro cell growth
For determining the effect of TSTs on cell growth, 4,000 cells were seeded per well in 96-well plates. After 24 hr, cells were treated with different concentrations of TST-A or TST-D. At the indicated time, cells were washed in PBS once, fixed in 100 ll/well 1% glutaraldehyde (Sigma-Aldrich) for 15 min, after the removal, then stained with 100 ll/well 0.5% crystal violet (Sigma-Aldrich) for 15 min. After washing out excess dye, 100 ll/well Sorenson's solution was added to elute dye from stained cells and subjected to densitometry measurement at OD 560 nm . The relative cell number was determined using control 5 1.
Plasmids and cell transfection
Human AR-V7 cDNA was obtained from Dr Jun Luo (Johns Hopkins Medical School) and AR-V7 minigene was provided by Dr Xuesen Dong (Vancouver Prostate Centre, University of British Columbia). Flag-tagged U2AF65 and hnRNP I plasmids were obtained from Dr James Manley (Columbia University) and Dr Allain Frede ric (Institute for Molecular Biology and Biophysics Eidgen o ssiche Technische Hochshule,
What's new?
For patients with metastatic prostate cancer, the reduction of androgen production or inhibition of androgen receptor activity is the standard treatment. Truncated AR variant 7 plays a critical role in not only refraction to androgen deprivation therapy but also progression to castration-resistant prostate cancer (CRPC) by promoting androgen-independent growth of CRPC cells. Currently, no effective agent can target AR-V7. The authors unveil the mechanism of action of alternative AR gene splicing and explore the potential of thailanstatins (TSTs) to inhibit AR-7 gene expression. TSTs appear to be a potent agent in suppressing CRPC cells in vitro and in vivo.
Switzerland). All the plasmid transfections were performed with Lipofectamine 3000 transfection kit (Life Technologies) according to the manufacturer's instructions.
Western blot and immunoprecipitation (IP)
Cells were harvested and lysed using ice-cold lysis buffer [150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tri (pH 8.0), protease inhibitor cocktail (Roche, Indianapolis, IN)] for 45 min or subjected to nuclear and cytoplasmic extraction (NE-PER; Pierce Biotechnology, Rockford, IL). Lysates were centrifuged at 13,000 rpm for 10 min at 48C. Equivalent amounts of protein were separated on 4-12% gradient NuPAGE Bis-Tris Plus Gels (Life Technologies) and transferred (Trans-Blot V R SD Semi-Dry Electrophoretic Transfer Cell, Bio-Rad, Hercules, CA) to nitrocellulose membranes. Membranes were blocked in TBS-Tween 20 containing 3% nonfat dry milk (w/v) for 1 hr and then incubated with primary antibodies overnight at 48C. Appropriate secondary antibodies conjugated with horseradish peroxidase and enhanced chemiluminescence (Pierce Biotechnology) with Supersignal V R West Dura Extended Duration Substrate kit (Thermo Fisher Scientific, Waltham, MA) were used to detected target proteins. For IP, the immunocomplexes were first precipitated with Dynabeads Protein G (Life Technologies) and then subjected to western blot analysis. Bands were addressed by densitometric scans and showed after normalizing to Actin.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted with Maxwell 16 LEV simplyRNA tissue kit (Promega, Madison, WI) and cDNA was made from 1 lg RNA using iScript Advanced cDNA Synthesis kit (Bio-Rad, Hercules, CA). qRT-PCR analysis was set up with SYBR Green qPCR Supermix kit (Life Technologies) and carried out in iCycler thermal cycler (Bio-Rad). The relative level of mRNA expression of each gene was determined by normalizing with 18S rRNA. All experiments were repeated at least twice in duplicates. The primers used in this experiment were listed in Supporting Information, Table S2 .
RNA pull-down assay RNA oligo (CUACAGUCAACAAUGUCUCUCUUUCAUAC UAGAAAAAUUC) was synthesized (Life Technologies) and biotinylated using Pierce RNA 3 0 -end Desthiobiotinylation Kit (Thermo Fisher Scientific). Biotinylated RNA oligo (50 pmol) was incubated with streptavidin magnetic beads (Thermo Fisher Scientific) at room temperature for 30 min and immobilized RNA oligo was incubated with 80 mg extracted nuclear protein in a binding buffer containing 50% glycerol and 50 mM NaCl at 48C for 2 hr. The beads were washed three times and proteins were eluted and then subjected to MS or western blot analysis.
Mouse xenografts, histology examination and immunohistochemistry (IHC) staining
22RV1 mixed with Matrigel (Thermo Fisher Scientific) was injected subcutaneously. Once tumor becomes palpable, TST-D (300 mg/kg/day) or DMSO (control) was delivered using ALZET osmotic pumps (DURECT Corporation, Cupertino, CA). Tumor volume was determined before and after injection and each tumor was excised and weighted then subjected to histological examination and target validation using western blot. All animal protocols were approved by the Institutional Animal Care and Use Committee in UT Southwestern Medical Center.
Hematoxylin and eosin (H&E) and IHC staining for cleaved Caspase-3 were carried out in formalin-fixed, paraffin-embedded tissue sections with 5-6 lm sections. For IHC, sections were subjected to heat-induced antigens retrieval (Tris/EDTA, pH 9.0) for 30 min at 978C then to Dako envision detection using DAKO autostainer Link48 (Dako, Carpinteria, CA).
Statistical analysis
All error bars in graphical data represent mean 6 SD. Student's two-tailed t test was used for the determination of statistical relevance between groups, and p < 0.05 was considered statistically significant. All statistical analyses were performed with GraphPad Prism software.
Results
The effect of TSTs on prostate epithelial cells FR901464 (FR), a bacterial natural product from a Pseudomonas species, and spliceostatin A (SSA), a methylated derivative of FR, are prototypic pre-mRNA splicing inhibitors and exhibited potent antiproliferative activities. 24 However, the inherent chemical instability of FR and SSA has hindered their development. Recently, we identified several natural FR analogs, namely, thailanstatins (TST-A, TST-B, TST-C and TST-D) 22 Fig. S1B ). In addition, both agents inhibited the cell growth of
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these 3 CRPC cell lines in both dose-and time-dependent manners (Figs. 1c and 1d ).
The effect of TST-A and TST-D on the expression of fulllength AR (AR-FL) and AR-V7
Knowing TST as a potent splicing inhibitor, we determined the steady-state levels of AR-V7 mRNA in VCaP, 22RV1 and LN95 cells treated with different concentrations of TST-A or TST-D. As shown in Figure 2a and Supporting Information, Figure S2A , the mRNA levels of both AR-V7 and AR-FL were suppressed by TST-A or TST-D in a dose-dependent manner. Similar to mRNA results, the protein levels of AR-V7 and other AR-Vs were significantly decreased with the incremental concentrations of TST-A or TST-D (Fig. 2b) . Also, immunostaining data indicated that nuclear AR-V7 disappeared in treated cells ( Supporting Information, Fig. S3 ).
In addition, time course data indicated that the inhibitory effect of TSTs on AR-V7 (Fig. 2c) or AR-FL (Supporting Information, Fig. S2B ) mRNA expression could be detected as early as 2 hr after treatment. Accordingly, AR-V7 protein was reduced (Fig. 2d ) but less for AR-FL protein (Supporting Information, Fig. S2B ) that may be due to the longer half-life of AR-FL protein. 25 Nevertheless, the effect of TSTs on AR expression appeared to be gene specific after examining several other genes (Supporting Information, Fig. S4 ) with alternative splicing variants that did not show any consistent inhibition.
Meanwhile, PSA expression as a reporter of AR activity was also detected by PCR. As shown in Figure 2e , PSA reduction could be detected 2 hr after treatment. We further examined the effect of TST on gene without alternative splicing variants such as AKR1C3 (a steroidogenesis enzyme in androgen synthesis) and both PCR and western results ( Fig.  2a and Supporting Information, Fig. S2C ) showed that the expression of AKR1C3 was not impacted by TSTs. It appeared that the inhibitory effect of TSTs was mainly on AR gene expression, which could be due to the actively expression of AR gene in CRPC cell.
AR-V7 as a major target of TST-D-elicited cytotoxicity
To delineate the role of AR-V7 or AR-FL in TST-elicited growth inhibition of CRPC, both 22RV1 and VCAP cells were transiently transfected with exogenous AR-V7 or AR-FL cDNA vector prior to drug treatment. As shown in Figures 3a and 3b , Cancer Therapy and Prevention expression was not affected by TST-D while only endogenous AR-V7 or AR-FL was significantly decreased by TST-D (Fig. 3 and Supporting Information, Fig. S5 ), suggesting the effect of TSTs on AR gene splicing.
The mechanism of TST action on AR gene splicing
To unveil the mechanism of TSTs on AR gene splicing, AR minigene 26 was employed as a splicing reporter vector in 22RV1 and VCaP cells to determine the effect of TSTs, AR-V7 or AR-FL can be detected using different primers. In addition, HEK293 cell without endogenous AR expression was used as well. As shown in Figure 4 and Supporting Information, Figure   S6 , the expression of cDNA products that mimic AR-V7 and AR-FL were decreased in a dose-dependent manner with treatment of TST-A and TST-D, which is similar to the effect of TSTs on inhibiting the endogenous AR gene expression.
As TSTs can effectively inhibit the expression of AR-V7 minigene that contains intronic splicing enhancers (ISE) critical for the formation of AR-V7 mRNA, ISE binding protein, U2AF65, has been demonstrated to play an essential role in AR-V7 pre-mRNA splicing 26 by interacting with other splicing factors such as SF3B complex during pre-mRNA splicing. We therefore used ISE in an RNA pull-down assay and conducted MS analysis to identify the potential splicing factors that are necessary in AR-V7 splicing. SAP155 (also called SF3B1), U2AF65 and U2AF35 appeared to be potential candidates (Supporting Information, Table S3 ). We first surveyed the effect of TST-D on the expression of both U2AF65 and SAP155 in VCAP, 22RV1 and LN95, and found that TST-D did not alter the steady-state levels of expression of either protein (Fig. 5a) , however, TST-D can block the interaction between U2AF65 and SAP155. Furthermore, by transfecting U2AF65 cDNA expression vector into VCaP, 22RV1 and LN95 cells, we observed that exogenous U2AF65 expression could recover splicing procedure and upregulate AR or AR-V7 expression in TST-D-treated cells in a dose-dependent manner. Under the same experimental conditions, we noticed that the expression of neither AKR1C3 nor actin was affected, suggesting that gene splicing of both genes is not highly active in these cells (Fig. 5c) . Meanwhile, we carried out RNA pull-down assay using synthetic RNA oligonucleotides representing AR-V7 ISE to determine whether TST-D could decrease the binding of splicing factor to ISE clearly indicated that less binding of U2AF65/SAP155 complex to ISE of AR-V7 in the presence of TST-D (Fig. 5d) Recent data 27, 28 indicated that U2AF35 is a critical factor for exon skipping. However, it did not appear to be involved in AR-V7 splicing (Fig. 5b and Supporting Information,  Fig. S7 ). In addition, RNA pull-down (Fig. 5d ) and MS data (Supporting Information, Table S3) indicated that U2AF35 did not directly associate with U2AF65/SAP155 complex nor interact with ISE implying that U2AF35 are not involved in AR-V7 gene splicing. Collectively, these data conclude that the mechanism of TST-D is to target the assembly of U2AF65/SAP155 complex that is critical for the splicing of AR-V7 pre-mRNA.
The evaluation of in vivo efficacy of TST-D in CRPC therapy
To examine the in vivo effect of TSTs, we employed a xenograft model using Enzalutamide-resistant 22RV1 25 and preliminarily tested TST-D in this study. As shown in Figure 6a and Supporting Information, Figure S8A , TST-D significantly inhibited the tumor growth. TST-D treatment was able to suppress the protein expression of AR-V7 (or other AR-Vs) and prostate-specific antigen (PSA) in a dose-dependent manner ( Fig. 6b and Supporting Information, Fig. S8B ), reflecting overall AR activities. Similar to the in vitro data (Fig. 2b) , AKR1C3 remained unchanged in tumor cells during the course of treatment. The apoptotic marker such as cleaved Caspase-3 was significantly elevated but proliferation maker such as Ki67 protein was significantly decreased in the treated tumors (Fig. 6b) . Histologic examination also unveiled that the treated tumors exhibited significant drug-elicited cell apoptosis compared with control (Fig. 6c) . Consistent with Western blot data, the IHC result indicated that the apoptotic marker such as cleaved Caspase-3 was significantly elevated in the treated tumors (Fig. 6c) . Taken together, these results suggested that TST-D could be a promising agent to target CRPC tumor expressing AR-Vs. 
Discussion
In the past few years, several new agents have been approved for metastatic CRPC patients, 10, 11 but those new agents, such as the CYP17 inhibitor (i.e., Abiraterone), second-generation AR antagonist (i.e., Enzalutamide) and an androgen receptor N-terminal domain antagonist EPI-001 29 still target androgen synthesis and AR because AR remains active even in CRPC. Despite of overwhelming response to these new regimens, the recurrent cancer eventually relapses resulted in the mortality of this disease. Therefore, the mechanism(s) leading to drug resistance become the focal point of combating CRPC. Noticeably, the appearance of several AR-Vs in CRPC cells after ADT becomes one of the suspicious causes of the failure of ADT. Truncated AR-Vs without LBD such as AR-V7 are functional active to promote androgen-independent growth for CRPC cells; most significantly, all anti-AR agents have no effect on these proteins. As expected, the presence of AR-V7 in circulating tumor cells from CRPC patients is highly correlated with patient survival. 30 Currently, several studies have attempted to develop some new drugs to target AR-Vs. For example, AR degradation compound ASC-J9, 31 BRD4 inhibitor JQ1 32 and CYP17 inhibitor galeterone 33 have been shown to suppress AR-Vs protein expression. Meanwhile, antisense oligonucleotides (ASO) specifically for AR can target AR genes and its splice variants have been reported. 34 Additional strategy is to target the transactive domain of AR-Vs by developing small molecular inhibitors or peptidomimetics, 35 in hope to suppress their activities by preventing their binding to Collectively, AR-Vs are mostly generated by alternative gene splicing in CRPC cells, which offer an additional targeting strategy. Although programmed alternative pre-mRNA splicing is commonly associated with normal cells, more active pre-mRNA splicing or aberrant splicing is often detected in cancer cells. 20, 21 As such, therapeutic intervention targeting the pre-mRNA splicing machinery (spliceosome) has gained considerable attention in recent years. 24 There have been a significant number of explorations to develop spliceosome inhibitors including FR, SSA, pladienolides, and sudemycins. 24 Among them, spliceosome inhibitor E7107 has been put to phase I study and shown the desired target effect with dose-dependent pharmacokinetic behavior clinically. 36 These results further highlighted that spliceosome inhibitors are becoming next promising agent to target cancer. Herein, TSTs appeared to be highly potent agents (IC 50 in the nanomolar range) to inhibit CRPC cells growth by targeting AR pre-mRNA splicing (Figs. 1 and 4) . We confirmed AR-V7 as a major target of TSTs because CRPC cells are highly dependent on AR-V7 for their growth and survival (Fig. 3) . Our data further unveiled that the possible mechanism of action of TSTs is to interfere splicing factors binding between U2AF65 and SAP155 and further prevent the binding of splicing complex to 3 0 splice site (SS) of AR-V7 pre-mRNA (Figs. 5b and 5d) . U2AF has been shown to play a key role in recognizing the alternative 3 0 -SS of pre-mRNA, For example, in leukemia, 27 U2AF35 but not U2AF65 is responsible for exon skipping. In PCa, Liu et al. identified U2AF65 as one of key factors in AR-V7 gene splicing. 26 Indeed, our data indicated that elevated U2AF65 could significantly increase AR-V7 protein expression but not steroidogenesis gene (e.g., AKR1C3) or other house-keeping gene (e.g., actin) (Fig. 5c) , which may also imply that AR-V gene splicing is highly active in CRPC cells compared with these genes. Nevertheless, U2AF35 appeared not to participate in AR-V7 gene splicing ( Supporting Information, Figs. S5B and S5C ). On the other hand, it is very likely that TSTs can target gene splicing of other genes in CRPC cells. For example, proteins such as CD44 and VEGF with different isoforms derived from alternative splicing 37 in PCa cells could be the potential target(s) of TSTs, which warrants a more comprehensive study in the future.
Based on the mechanism of action of TSTs with respect to the "specificity" of alternative gene splicing unveiled from this study, we also recognize the potential challenge for its side effect once it is delivered systematically. Alternatively, engineering a PCa-specific delivery vehicle could reduce any undesirable side effect. On the other hand, based on its structural functional activities on complex formation of splicing factors, it is possible to design different analogs with high specificity.
In conclusion, our data offer a new therapeutic strategy to target AR-V7 that plays a critical role in not only the refraction to ADT but also the growth and survival of CRPC. Although we only delineated the underlying mechanism of TSTs in intervening AR-V7 gene splicing, we believe TSTs can target other AR-Vs and other gene products generated from active alternative splicing in CRPC cells. Thus, TSTs have a great clinical potential to be an effective therapeutic for recurrent CRPC.
